Form 4: Protara Therapeutics Director Gregory SARGENT Acquires 10,000 Stock Options

Director Gregory SARGENT acquired 10,000 stock options in Protara Therapeutics, Inc. on June 7, 2024, at an exercise price of $2.67.

Summary

• On June 7, 2024, Gregory SARGENT, a director of Protara Therapeutics, Inc., acquired 10,000 stock options.
• The exercise price of these options is $2.67.
• The options vest in equal monthly installments over 12 months, fully vesting by the next annual stockholder meeting or upon a change of control, contingent on continuous service as a board member.
• The expiration date for these options is June 6, 2034.
• Following the transaction, SARGENT directly owns 10,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and aligns director interests with shareholders.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a commitment to the company's long-term performance, with full vesting contingent on continued service and potentially accelerated by a change of control.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their directors and officers.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially driving long-term value creation.

Key Dates